Skip to main content
SpringerLink
Log in

Effects of Long-Term Treatment with Human Recombinant Erythropoietin in Patients on CAPD

  • Conference paper
New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 260))

Abstract

Anemia is a common feature in patients with chronic renal failure on regular dialysis treatment. The inappropriate low level of serum erythropoietin is known to be the major cause of anemia in these patients1. The development of recombinant human erythropoietin (rHuEPO) offers for the first time the possibility of an effective and continuous correction of renal anemia2 , 3 . In recent publications several authors described an increase of hematocrit in patients undergoing regular hemodialysis during treatment with rHuEPO2–7. In the initial trials rHuEPO treatment was associated with various adverse effects such as hypertension, convulsions, fistula clotting, and increased serum creatinine, urea, and potassium 2–4.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Eschbach, J.W., Adamson, J.W.:Anemia of end-stage renal disease (ESRD). Kidney Int. 28:1 (1985).

    Article  PubMed  CAS  Google Scholar 

  2. Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., Cotes, P.M.: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic hemodialysis. Lancet ii:1175 (1986).

    Article  Google Scholar 

  3. Eschbach, J.W., Egrie, J.C., Downing, M.R., Browne, J.K., Adamson, J.W.: Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: Results of the phase I and II clinical trial. New Engl. J. Med. 316:73 (1987) .

    Article  PubMed  CAS  Google Scholar 

  4. Bommer, J., Alexiou, C., Müller-Bühl, E., Eifert, J., Ritz, E.: Recombinant human erythropoietin therapy in hemodialysis patients — dose determination and clinical experience. Nephrol. Dial. Transplant. 2:238 (1987).

    PubMed  CAS  Google Scholar 

  5. Casati, S., Passerini, P., Campise, M.R., Graziani, G. , Cesana, B., Perisic, M., Ponticelli, C.: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br. med. J. 295:1017 (1987).

    Article  CAS  Google Scholar 

  6. Bommer, J., Kugel, M., Schoeppe, W., Brunkhorst, R., Samtleben, W., Bramsiepe, P., Scigalla, P.: Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease. Contr. Nephrol. Vol. 66, p 85, Karger, Basel (1988).

    CAS  Google Scholar 

  7. Verbeelen, D., Hauglustaine, D., Sennesael, J.: Treatment of the anemia of end-stage renal disease with recombinant human erythropoietin. Neth. J. Med. 33:60 (1988).

    PubMed  CAS  Google Scholar 

  8. Brown, C.D., Kieran, M., Zhao, Z.-H., Larson, R.H. , Friedmann, E.A.: Treatment of azotemic, anemic patients with recombinant human erythropoietin (rHuEPO) raises whole blood viscosity (WB) proportional to hematocrit. Kidney Int. 33:184 (1988).

    Google Scholar 

  9. Nonnast-Daniel, B., Creutzig, A., Kühn, K., Bahlmann, J.f Reimers, E., Brunkhorst, R., Caspary, L., Koch, K.M.: Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. Contr. Nephrol. Vol. 66, p 185, Karger, Basel (1988).

    CAS  Google Scholar 

  10. Gurney, C.W., Jacobson, L.O., Goldwasser, E.: The physiologic and clinical significance of erythropoietin. Ann. Intern. Med. 49:353 (1958).

    Google Scholar 

  11. Chaplin, H., Mollison, P.L.: Red cell life-span in nephritis and hepatic cirrhosis. Clin. Sci. 12:351 (1953).

    PubMed  Google Scholar 

  12. Meytes, D., Bogin, E., Ma, A., Dukes, P.P., Massry, S.G.: Effect of parathyroid hormone on erythropoiesis. J. Clin. Invest. 67:1263 (1981).

    Article  PubMed  CAS  Google Scholar 

  13. Radtke, H.W., Rege, A.B., LaMarche, M.B., Bartos, D., Campbell, R.A., Fischer, J.W.: Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J. Clin. Invest. 67:1623 (1981).

    Article  CAS  Google Scholar 

  14. Bargmann, J.M., Breborowicz, A., Rodela, H., Sombolos, K., Oreopoulos, D.G.: Intraperitoneal administration of recombinant human erythropoietin in uremic animals. Perit. Dial. Int. 8:249 (1988).

    Google Scholar 

  15. Boelaert, J., Schurgers, H., Matthys, E., Daneeis, R., De Cre, M., Bogaert, M.: Recombinant human erythropoietin pharmacokinetics in CAPD patients: Comparison of intravenous, subcutaneous and intraperitoneal routes. Nephrol. Dial. Transplant. 3:493 (1988).

    Google Scholar 

  16. Macdougall, J.C., Roberts, D.E., Dharmasena, A.D., Coles, G.A.: The pharmacokinetics of IV and IP recombinant erythropoietin in CAPD patients. Perit. Dial. Int. 9:108 (abstract) (1989).

    Google Scholar 

  17. Nolph, K.D., Mactier, R., Khanna, R., Twardowski, Z.J., Moore, H., McGary, T.: The kinetics of ultrafiltration during peritoneal dialysis: The role of lymphatics.Kidney Int. 32:219 (1987).

    Article  PubMed  CAS  Google Scholar 

  18. Grützmacher, P., Scheuermann, E., Low, I., Bergmann, M., Rauber, K., Baum, R., Heuser, J., Schoeppe, W.: Correction of renal anaemia by recombinant human erythropoietin: Effects on myocardial function. Contr. Nephrol. Vol. 66, p 176, Karger, Basel (1988).

    Google Scholar 

  19. Verbeelen, D., Bossuyt, A., Smitz, J., Herman, A., Dratwa, M., Jonckheer, M.H.: Hemodynamics of patients with renal failure treated with recombinant human erythropoietin. Clin. Nephrol. 31:6 (1989).

    PubMed  CAS  Google Scholar 

  20. Steinhauer, H.B., Lubrich-Birkner, I., Dreyling, K.W., Hörl, W.H., Schollmeyer, P.: Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis. Nephron 53:87 (1989) .

    Article  Google Scholar 

  21. Böcker, A., Braumann, K.-M., Brunkhorst, R., Böning, D.: Effect of erythropoietin treatment on 02 affinity and performance in patients with renal anemia. Contr. Nephrol. Vol. 66, p 165, Karger, Basel (1988).

    Google Scholar 

  22. Slingeneyer, A., Canand, B., Mion, C.: Permanent loss of ultrafiltration capacitiy of the peritoneum in long-term peritoneal dialysis. An epidemiological study. Nephron 33:133 (1983).

    Article  PubMed  CAS  Google Scholar 

  23. Wideröe, T.-E., Smeby, L.C., Mjaland, S., Dahl, K., Berg, K.J., Aas, T.W.: Long-term changes of transperitoneal water transport during continuous ambulatory peritoneal dialysis. Nephron 38:238 (1984).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Nephrology, University of Freiburg, Germany

    Hjalmar B. Steinhauer

Authors
  1. Hjalmar B. Steinhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Universitätsklinik, Freiburg, Federal Republic of Germany

    W. H. Hörl  & P. J. Schollmeyer  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Plenum Press, New York

About this paper

Cite this paper

Steinhauer, H.B. (1989). Effects of Long-Term Treatment with Human Recombinant Erythropoietin in Patients on CAPD. In: Hörl, W.H., Schollmeyer, P.J. (eds) New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis. Advances in Experimental Medicine and Biology, vol 260. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5718-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5718-6_17

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-5720-9

  • Online ISBN: 978-1-4684-5718-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation